^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Sarcoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Angiosarcoma: Other Recommended Regimens…Sorafenib